After-Hours Stock Movers 02/24: (MRNA) (MMSI) (NLS) Higher; (PANW) (EVER) (SHAK) Lower (more...)
Today's After-Hours Stock Movers
Moderna (NASDAQ: MRNA) 14.7% HIGHER; shipped the first batch of its coronavirus vaccine to U.S. government researchers who will launch the first human tests, according to Dow Jones.
Palo Alto Networks (NYSE: PANW) 14.2% LOWER; reported Q2 EPS of $1.19, $0.07 better than the analyst estimate of $1.12. Revenue for the quarter came in at $816.7 million versus the consensus estimate of $843.26 million. Palo Alto Networks sees Q3 2020 EPS of $0.96-$0.98, versus the consensus of $1.25. Palo Alto Networks sees Q3 2020 revenue of $835-850 million, versus the consensus of $873 million. Palo Alto Networks sees FY2020 EPS of $4.55-$4.65, versus the consensus of $4.96. Palo Alto Networks sees FY2020 revenue of $3.35-3.39 billion, versus the consensus of $3.47 billion.
EverQuote (NASDAQ: EVER) 12.9% LOWER; reported Q4 EPS of ($0.04), $0.02 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $73.8 million versus the consensus estimate of $68.13 million. EverQuote sees Q1 2020 revenue of $77-79 million, versus the consensus of $75.42 million. EverQuote sees FY2020 revenue of $315-325 million, versus the consensus of $310.54 million.
Shake Shack (NYSE: SHAK) 12% LOWER; reported Q4 EPS of $0.06, $0.06 better than the analyst estimate of $0.00. Revenue for the quarter came in at $151.4 million versus the consensus estimate of $153.14 million. Shake Shack sees FY2020 revenue of $712-720 million, versus the consensus of $737.1 million.
Kratos Defense (NASDAQ: KTOS) 11.4% LOWER; reported Q4 EPS of $0.09, $0.01 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $185.1 million versus the consensus estimate of $197.34 million. Kratos Defense sees Q1 2020 revenue of $160-170 million, versus the consensus of $190.54 million.
Merit Medical Systems Inc. (NASDAQ: MMSI) 10.5% HIGHER; reported Q4 EPS of $0.40, $0.06 better than the analyst estimate of $0.34. Revenue for the quarter came in at $257.9 million versus the consensus estimate of $252.31 million. Merit Medical Systems Inc. sees FY2020 EPS of $1.58-$1.68, versus the consensus of $1.56.
Nautilus (NYSE: NLS) 8.5% HIGHER; reported Q4 EPS of $0.12, $0.26 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $104.2 million versus the consensus estimate of $99.78 million. The Company does not plan to provide specific guidance on an ongoing basis but due to the timing of the fourth quarter 2019 release and the early stages of its business transformation, it is providing the following commentary: The Company expects EBITDA from continuing operations to be a loss in the range of $4.0 million to $1.0 million. Capital expenditures for 2020 are anticipated to be in the range of $8.0 million to $10.0 million.
Exact Sciences Corporation (NASDAQ: EXAS) 8% LOWER; announced an underwritten public offering of $850 million aggregate principal amount of convertible senior notes due 2028 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3.
Clovis Oncology (NASDAQ: CLVS) 8% LOWER; reported Q4 EPS of ($1.81), $0.10 worse than the analyst estimate of ($1.71). Revenue for the quarter came in at $39.3 million versus the consensus estimate of $38.97 million.
Tandem Diabetes (NASDAQ: TNDM) 7.4% LOWER; reported Q4 EPS of $0.04, $0.09 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $108.4 million versus the consensus estimate of $109.22 million. Tandem Diabetes sees FY2020 revenue of $450-465 million, versus the consensus of $444.62 million.
Keysight Technologies (NYSE: KEYS) 7% HIGHER; reported Q1 EPS of $1.26, $0.19 better than the analyst estimate of $1.07. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.06 billion. Keysight Technologies sees Q2 2020 EPS of $1.28-$1.38, versus the consensus of $1.30. Keysight Technologies sees Q2 2020 revenue of $1.1138-1.178 billion, versus the consensus of $1.15 billion.
Guardant Health (NASDAQ: GH) 6.3% LOWER; reported Q4 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $62.9 million versus the consensus estimate of $54.83 million. Guardant Health sees FY2020 revenue of $275-285 million, versus the consensus of $273.1 million.
HP Inc. (NYSE: HPQ) 5% HIGHER; announced a multi-year strategic and financial value creation plan that is expected to deliver $3.25 to $3.65 non-GAAP diluted net EPS by 2022. This significant expected earnings growth is supported by HPs market leadership and track record of execution across Personal Systems, Print, and 3D Printing & Digital Manufacturing, disciplined and sustained cost actions, as well as a new capital return program of approximately $16 billion during fiscal 2020 to fiscal 2022.
Arlo Technologies, Inc. (NYSE: ARLO) 2.7% HIGHER; reported Q4 EPS of ($0.26), $0.05 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $122.4 million versus the consensus estimate of $121.02 million. Arlo Technologies, Inc. sees Q1 2020 EPS of ($0.44)-($0.47), versus the consensus of ($0.29). Arlo Technologies, Inc. sees Q1 2020 revenue of $60-70 million, versus the consensus of $74.11 million.
Intuit (Nasdaq: INTU) 2% HIGHER; announced that it has agreed to acquire Credit Karma, the consumer technology platform with more than 100 million members in the U.S., Canada and U.K., for approximately $7.1 billion in cash and stock. By agreeing to acquire Credit Karma, a company with nearly $1 billion in unaudited revenue in calendar year 2019, up 20% from the previous year, Intuit accelerates its mission of powering prosperity around the world.
MasterCard (NYSE: MA) 1.5% LOWER; Lowers Guidance Due to Impact of the CoronavirusFeb 24, 2020 05:38 PM
United Airlines (NYSE: UAL) 0.6% LOWER; is withdrawing all full-year 2020 guidance due to coronavirus: